[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
A phase 1/2 trial of [18F]FPyQCP in colorectal cancer, ovarian cancer, gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Blue Earth Diagnostics, now recruiting.
Overview
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications is a phase 1/2 interventional study registered as NCT07432633 by Blue Earth Diagnostics, with 71 participants planned, started 2026-02-19 and due to reach its primary completion in 2028-01-31. Interventions recorded: [18F]FPyQCP.
Similar pages
not linked directly; found by shared links- Trial[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Shares Blue Earth Diagnostics (Bracco) and the tag pipeline.
- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares Fluorine-18 and the tag pipeline.
- TrialImaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Shares Fluorine-18 and the tag pipeline.
- TrialUsing 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Shares Fluorine-18 and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares Fluorine-18 and the tag pipeline.
- TrialPhase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases
Shares Fluorine-18 and the tag pipeline.
- TrialA Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Shares Fluorine-18 and the tag pipeline.
- TrialOpen-Label Study of 18F-mFBG for Imaging Neuroblastoma
Shares Fluorine-18 and the tag pipeline.